Premium
HTR2C haplotypes and antipsychotics‐induced weight gain: X‐linked multimarker analysis
Author(s) -
De Luca Vincenzo,
Müller Daniel J.,
Hwang Rudi,
Lieberman Jeffrey A.,
Volavka Jan,
Meltzer Herbert Y.,
Kennedy James L.
Publication year - 2007
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.868
Subject(s) - haplotype , weight gain , clozapine , confounding , antipsychotic , medicine , polymorphism (computer science) , obesity , genetics , oncology , gene , body weight , schizophrenia (object oriented programming) , biology , genotype , psychiatry
Abstract The 5HT2C receptor (HTR2C) has been hypothesized to represent an important modulator in feeding behavior. Evidence was based on the observation that knock‐out mice for the HTR2C receptor gene develop obesity and that many antipsychotics (AP) with potent HTR2C antagonism may induce weight gain in susceptible individuals. Pharmacogenetic studies focusing either on the Cys23Ser polymorphism or on the −759C/T promoter polymorphism of the X‐linked HTR2C receptor gene revealed significant findings for the −759C/T polymorphism, however, no study has performed haplotype analyses for both polymorphisms. Methods We analyzed three functional polymorphisms (Cys23Ser, −759C/T, and (GT)12–18/(CT) 4–5) of the HTR2C in 139 schizophrenic patients mainly treated with clozapine. Weight gain was assessed over a time course of 6–14 weeks (mean 8.2 weeks). Results Single marker and haplotype analysis revealed no significant associations with AP‐induced weight gain. The haplotype Long‐C‐Ser was protective against weight gain, but the number of subjects available for that analysis was small. Conclusions Our pilot study did not detect any significant haplotype conferring risk for antipsychotic‐induced weight gain although the statistical model took into account the X‐linked heterogeneity and did correct for confounding factors (i.e., ethnicity, medications, clinical response, time of assessment). Copyright © 2007 John Wiley & Sons, Ltd.